Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS)

Compare
13.30
-0.44
(-3.20%)
At close: 3:00:02 PM GMT+8
Loading Chart for 603538.SS
  • Previous Close 13.74
  • Open 13.64
  • Bid 13.29 x --
  • Ask 13.30 x --
  • Day's Range 13.13 - 13.70
  • 52 Week Range 9.99 - 15.41
  • Volume 4,946,134
  • Avg. Volume 5,475,356
  • Market Cap (intraday) 2.907B
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) 166.25
  • EPS (TTM) 0.08
  • Earnings Date --
  • Forward Dividend & Yield 0.02 (0.15%)
  • Ex-Dividend Date Jul 15, 2024
  • 1y Target Est --

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. Ningbo Menovo Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Ningbo, China.

www.menovopharm.com

2,353

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603538.SS

View More

Performance Overview: 603538.SS

Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603538.SS
4.64%
SSE Composite Index (000001.SS)
2.26%

1-Year Return

603538.SS
10.10%
SSE Composite Index (000001.SS)
8.94%

3-Year Return

603538.SS
63.79%
SSE Composite Index (000001.SS)
2.02%

5-Year Return

603538.SS
47.88%
SSE Composite Index (000001.SS)
16.17%

Compare To: 603538.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603538.SS

View More

Valuation Measures

Annual
As of 4/15/2025
  • Market Cap

    3.00B

  • Enterprise Value

    3.63B

  • Trailing P/E

    171.75

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.64

  • Price/Book (mrq)

    1.38

  • Enterprise Value/Revenue

    2.94

  • Enterprise Value/EBITDA

    57.64

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.64%

  • Return on Assets (ttm)

    0.55%

  • Return on Equity (ttm)

    1.07%

  • Revenue (ttm)

    1.24B

  • Net Income Avi to Common (ttm)

    20.3M

  • Diluted EPS (ttm)

    0.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    785.91M

  • Total Debt/Equity (mrq)

    62.46%

  • Levered Free Cash Flow (ttm)

    -48.07M

Research Analysis: 603538.SS

View More

Company Insights: 603538.SS

Research Reports: 603538.SS

View More

People Also Watch